PUBLICATIONS

 

 *Adriaenssens N, Coenen S, Tonkin-Crine S, Verheij TJ, Little P, Goossens H; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): disease-specific quality indicators for outpatient antibiotic prescribing. BMJ Qual Saf. 2011 (in press).

 

*Adriaenssens N, Coenen S, Kroes AC, Versporten A, Vankerckhoven V, Muller A, Blix HS, Goossens H; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): systemic antiviral use in Europe. J Antimicrob Chemother. 2011 Aug;66(8):1897–1905.

 

*Adriaenssens N, Coenen S, Muller A, Vankerckhoven V, Goossens H; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient systemic antimycotic and antifungal use in Europe. J Antimicrob Chemother. 2010 Apr;65(4):769–74.

 

*Adriaenssens N, Goossens H, Coenen S; ESAC Project Group. Comment on: Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemother. 2009 Dec;64(6):1347.

 

Aissa K, Madhi F, Ronsin N, Delarocque F, Lecuyer A, Decludt B, Remus N, Abel L, Poirier C, Delacourt C; CG94 Study Group. Evaluation of a model for efficient screening of tuberculosis contact subjects. Am J Respir Crit Care Med. 2008 May;177(9):1041–7.

 

Bannister B, Puro V, Fusco FM, Heptonstall J, Ippolito G; EUNID Working Group. Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis. 2009 Jan;9(1):45–56.

 

Barrail-Tran A, Morand-Joubert L, Poizat G, Raguin G, Le Tiec C, Clavel F, Dam E, Chêne G, Girard PM, Taburet AM; Puzzle–1 (ANRS 104) Study Group. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen. Antimicrob Agents Chemother. 2008 May;52(5):1642–6.

 

*Coenen S, Muller A, Adriaenssens N, Vankerckhoven V, Hendrickx E, Goossens H; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe. J Antimicrob Chemother. 2009 Jul;64(1):200–5.

 

*Coenen S, Ferech M, Haaijer-Ruskamp FM, Butler CC, Vander Stichele RH, Verheij TJ, Monnet DL, Little P, Goossens H; ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual Saf Health Care. 2007 Dec;16(6):440–5.

 

*Davey P, Ferech M, Ansari F, Muller A, Goossens H; ESAC Project Group. Outpatient antibiotic use in the four administrations of the UK: cross-sectional and longitudinal analysis. J Antimicrob Chemother. 2008 Dec;62(6):1441–7.

 

Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe–ANRS 121 Trial. J Antimicrob Chemother. 2008 Oct;62(4):797–808.

 

*Elseviers MM, Ferech M, Vander Stichele RH, Goossens H; ESAC Project Group. Antibiotic use in ambulatory care in Europe (ESAC data 1997–2002): trends, regional differences and seasonal fluctuations. Pharmacoepidemiol Drug Saf. 2007 Jan;16(1):115–23.

 

*Goossens H, Ferech M, Coenen S, Stephens P; ESAC Project Group. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis. 2007 Apr 15;44(8):1091–5.

 

Lafaurie M, Collin F, Bentata M, Garré M, Leport C, Levy Y, Goujard C, Chêne G, Molina JM; Alize study group. Switch from zidovudine– to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. J Antimicrob Chemother. 2008 Nov;62(5):1122–9.

 

Le Moing V, Taïeb A, Longuet P, Lewden C, Delcey V, Drobacheff MC, Chêne G, Leport C; ANRS C08 (Aproco–Copilote) study group. Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretrovial drugs before conception. HIV Med. 2008 Nov;9(10):897–900.

 

Morlat P, Pereira E, Clayette P, Derreudre-Bosquet N, Ecobichon JL, Benveniste O, Saves M, Leport C; ANRS C08 Aproco–Copilote Study Group. Early evolution of plasma soluble TNF-alpha p75 receptor as a marker of progresion in treated HIV-infected patients. AIDS Res Hum Retroviruses. 2008 Nov;24(11):1383–9.

 

*Moulin G, Cavalié P, Pellanne I, Chevance A, Laval A, Millemann Y, Colin P, Chauvin C; Antimicrobial Resistance ad hoc Group of the French Food Safety Agency. A comparison of antimicrobial usage in human and veterinary medicine in France from 1999 to 2005. J Antimicrob Chemother. 2008 Sep;62(3):617–25.

 

Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA; Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008 Feb;12(2):128–38.

 

*Van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, Ferech M; European Antimicrobial Resistance Surveillance System Group; European Surveillance of Antimicrobial Consumption Project Group. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008 Nov;14(11):1722–30.